Two medical centers in SND gain nucleic acid testing qualifications

The IPE center for clinical laboratory and Oncocare Life, both in Suzhou New District, were among the first organizations to receive third-party COVID-19 nucleic acid testing qualifications in China.

The qualifications are intended to aid in Suzhou's epidemic prevention and control work.

The IPE lab has reserved roughly 100,000 new tubes and reagents for sampling and screening. Since Feb 14, the lab had tested an average of 10,000 tubes every day, issuing more than 40,000 reports, effectively alleviating the nucleic acid test pressure on local medical institutions.

Oncocare Life urgently mobilized more than 100,000 pieces of reagent materials as well as dozens of inspectors from its Harbin and Nanjing branches. It has also teamed up special nucleic acid testing members, who worked around the clock to ensure the testing of 10,000 tubes per day and issued a total of 50,000 reports.

The two organizations are both located in the MedPark, an industrial park dedicated to pharmaceuticals and medical devices in Suzhou Science and Technology Town.

The IPE center was established in February 2018 with a focus on providing professional high-tech clinical services for medical institutions and more accurate and targeted diagnosis and treatment testing services for patients.

Oncocare Life carries out high-quality research and development and features state-of-the-art clinical resources. It was identified as the designated practice base of Nanjing Medical University in 2020.